GRI GRI Bio, Inc.
-
GRI Bio Beat Consensus Estimates
Friday, August 14, 2026 · 12:00 AM ET
GRI Bio (GRI) reported a loss of $0.91 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $1.20 per share. The company beat consensus estimates by 24.17%.
GRI Bio Inc. is a clinical stage biopharmaceutical company which focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio Inc., formerly known as Vallon Pharmaceuticals Inc., is based in PHILADELPHIA, PA.
Reported Earnings
($0.91)
Earnings Whisper®
—
Consensus Estimate
($1.20)
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—